CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 262 filers reported holding CLOVIS ONCOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $1,000 | -87.5% | 100 | -86.2% | 0.00% | – |
Q4 2019 | $8,000 | +166.7% | 726 | +3.4% | 0.00% | – |
Q3 2019 | $3,000 | -78.6% | 702 | -22.7% | 0.00% | -100.0% |
Q2 2019 | $14,000 | -44.0% | 908 | -10.1% | 0.00% | 0.0% |
Q1 2019 | $25,000 | – | 1,010 | +6633.3% | 0.00% | – |
Q4 2018 | $0 | -100.0% | 15 | -99.9% | 0.00% | -100.0% |
Q3 2018 | $569,000 | +62.6% | 19,368 | +151.5% | 0.03% | +50.0% |
Q2 2018 | $350,000 | +28.7% | 7,700 | +49.5% | 0.02% | +10.0% |
Q1 2018 | $272,000 | +750.0% | 5,152 | +984.6% | 0.02% | +566.7% |
Q4 2017 | $32,000 | -95.1% | 475 | -94.0% | 0.00% | -94.9% |
Q3 2017 | $656,000 | -60.5% | 7,967 | -55.1% | 0.06% | -62.4% |
Q2 2017 | $1,661,000 | +1612.4% | 17,736 | +1058.5% | 0.16% | +1644.4% |
Q1 2017 | $97,000 | -63.7% | 1,531 | -74.5% | 0.01% | -71.9% |
Q4 2016 | $267,000 | -23.7% | 6,004 | +57.8% | 0.03% | -37.3% |
Q3 2015 | $350,000 | -55.0% | 3,806 | -57.0% | 0.05% | -53.2% |
Q2 2015 | $778,000 | +18.4% | 8,850 | 0.0% | 0.11% | +19.8% |
Q1 2015 | $657,000 | – | 8,850 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |